Compared to chemotherapy alone, the addition of VEGF inhibitor, bevacizumab, to paclitaxel or capecitabine treatment regimens significantly increases progression free‐survival and the objective response rate in HER2 negative locally recurrent or metastatic BC patients.111. This evidence concerns the gene VEGFA and breast cancer.